Cargando…
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333732/ https://www.ncbi.nlm.nih.gov/pubmed/36260763 http://dx.doi.org/10.1182/bloodadvances.2022009021 |
| _version_ | 1785070728491565056 |
|---|---|
| author | Picod, Adrien Benhamou, Ygal Bouzid, Raïda Veyradier, Agnès Coppo, Paul |
| author_facet | Picod, Adrien Benhamou, Ygal Bouzid, Raïda Veyradier, Agnès Coppo, Paul |
| author_sort | Picod, Adrien |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10333732 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103337322023-07-12 More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura Picod, Adrien Benhamou, Ygal Bouzid, Raïda Veyradier, Agnès Coppo, Paul Blood Adv Commentary The American Society of Hematology 2022-10-21 /pmc/articles/PMC10333732/ /pubmed/36260763 http://dx.doi.org/10.1182/bloodadvances.2022009021 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Commentary Picod, Adrien Benhamou, Ygal Bouzid, Raïda Veyradier, Agnès Coppo, Paul More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title | More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title_full | More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title_fullStr | More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title_full_unstemmed | More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title_short | More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| title_sort | more on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333732/ https://www.ncbi.nlm.nih.gov/pubmed/36260763 http://dx.doi.org/10.1182/bloodadvances.2022009021 |
| work_keys_str_mv | AT picodadrien moreontheuseoffrontlinecaplacizumabinimmunemediatedthromboticthrombocytopenicpurpura AT benhamouygal moreontheuseoffrontlinecaplacizumabinimmunemediatedthromboticthrombocytopenicpurpura AT bouzidraida moreontheuseoffrontlinecaplacizumabinimmunemediatedthromboticthrombocytopenicpurpura AT veyradieragnes moreontheuseoffrontlinecaplacizumabinimmunemediatedthromboticthrombocytopenicpurpura AT coppopaul moreontheuseoffrontlinecaplacizumabinimmunemediatedthromboticthrombocytopenicpurpura |